1-乙酰基哌啶-4-羧酸乙酯 | 69001-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-乙酰基哌啶-4-羧酸乙酯
• 英文名称: 1-acetyl-piperidine-4-carboxylic acid ethyl ester
• 英文别名: 1-Acetyl-piperidin-4-carbonsaeure-aethylester；ethyl 1-acetylpiperidine-4-carboxylate；ethyl-1-acetylpiperidine-4-carboxylate；N-acetyl ethyl isonipecotate；1-Acetyl-piperidin-4-carbonsaeure-ethylester
• CAS: 69001-10-1
• 化学式: C₁₀H₁₇NO₃
• mdl: MFCD01195307
• 分子量: 199.25
• InChiKey: SAIQQCUEISMNQC-UHFFFAOYSA-N

物化性质

• 沸点：
  103-104 °C(Press: 0.01 Torr)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-乙酰基哌啶-4-羧酸乙酯 在 氢气 、 二异丁基氢化铝 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  Novel Spiroketal Pyrrolidine GSK2336805 Potently Inhibits Key Hepatitis C Virus Genotype 1b Mutants: From Lead to Clinical Compound

  摘要：

  [GRAPHICS]Rapid clinical progress of hepatitis C virus (HCV) replication inhibitors, including these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatment. Herein, we describe our explorations of diverse spiropyrrolidine motifs in novel NS5A inhibitors and a proposed interaction model. We discovered that the 1,4-dioxa-7-azaspiro[4.4]nonane motif in inhibitor 41H (GSIC2236805) supported high potency against genotypes la and lb as well as in genotype 1b L31V and Y93H mutants. Consistent with this, 41H potently suppressed HCV RNA in the 20-day RNA reduction assay. Pharmacokinetic and safety data supported further progression of 41H to the clinic.

  DOI：

  10.1021/jm4013104
• 作为产物：
  描述：

  4-哌啶甲酸 、 原乙酸三乙酯 反应 24.0h， 以91%的产率得到1-乙酰基哌啶-4-羧酸乙酯
  参考文献：
  名称：

  Concurrent esterification and N-acetylation of amino acids with orthoesters: a useful reaction with interesting mechanistic implications

  摘要：

  The concurrent esterification and N-acetylation of amino acids has been studied with triethyl orthoacetate (TEOA) and triethyl orthoformate (TEOF). In a surprising finding, only 1 equiv of TEOA in refluxing toluene was necessary to convert L-proline and L-phenylalanine into the corresponding N-acetyl ethyl esters in good yield. The same transformation using TEOF was not effective. Stereochemical outcome and stoichiometric studies as well as structural variation of the amino acids in this reaction provided unexpected mechanistic insight. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.10.081

文献信息

• 4-[(.alpha.,.alpha.-diaryl)-hydroxymethyl]-1-piperidinylalkyl-cyclic
  申请人：A. H. Robins Company, Incorporated

  公开号：US04886794A1

  公开（公告）日：1989-12-12

  4-[(.alpha.,.alpha.-Diaryl)-hydroxymethyl]-1-piperidinylalkylcyclic carbamate derivatives having the formula: ##STR1## wherein; R is hydrogen, loweralkyl, cycloalkyl, phenyl and substituted phenyl; Ar and Ar.sup.1 are phenyl, substituted phenyl or pyridinyl; alk is a straight or branched hydrocarbon chain; R.sup.1 is loweralkyl substituted for hydrogen on a ring carbon. The compounds are useful antihistamines and in controlling allergic response.

  具有以下结构的4-[(.alpha.,.alpha.-二芳基)-羟甲基]-1-哌啶基烷基环状氨基甲酸酯衍生物的化学式：##STR1## 其中；R为氢、较低烷基、环烷基、苯基和取代苯基；Ar和Ar.sup.1为苯基、取代苯基或吡啶基；烷基为直链或支链烃链；R.sup.1为在环碳上取代氢的较低烷基。这些化合物对抗组织胺并控制过敏反应有用。
• PYRROLIDINYL SULFONE RORGAMMA MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191483A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的，例如，主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。
• Process for making substituted pyrazoles
  申请人：——

  公开号：US20030225108A1

  公开（公告）日：2003-12-04

  This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): 1 wherein R 3A , R 3B , R 3C , Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are as defined in the specification.

  这项发明通常涉及制备取代吡唑，取代吡唑的互变异构体，以及取代吡唑和互变异构体的盐的过程。这些取代吡唑在结构上对应于式（I）： 1 其中R 3A ，R 3B ，R 3C ，Y 1 ，Y 2 ，Y 3 ，Y 4 和Y 5 如规范中所定义。
• [EN] DIHYDROPYRAZOLOPYRIDINE COMPOUNDS<br/>[FR] COMPOSES DE DIHYDROPYRAZOLOPYRIDINE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004014910A1

  公开（公告）日：2004-02-19

  The present invention provides dihydropyrazolopyridine compounds represented by the formula (I):wherein each symbol is as defined in the specification, optically active forms thereof, and pharmaceutically acceptable salts thereof and hydrates thereof. The compounds of the present invention show a selective and strong inhibitory activity on glycogen synthase kinase-3 beta (GSK-3β), and are useful as medicaments for prevention and/or treatment of diabetes, diabetic complications and neurodegenerative diseases or as immunopotentiators.

  本发明提供了由式(I)表示的二氢吡唑吡啶化合物，其中每个符号如规范中定义，其光学活性形式，以及其药学上可接受的盐和水合物。本发明的化合物显示出对糖原合成酶激酶-3β（GSK-3β）的选择性和强烈的抑制活性，并可用作预防和/或治疗糖尿病、糖尿病并发症和神经退行性疾病或免疫增强剂的药物。
• A general method for the direct transformation of common tertiary amides into ketones and amines by addition of Grignard reagents
  作者：Pei-Qiang Huang、Yu Wang、Kai-Jiong Xiao、Ying-Hong Huang

  DOI：10.1016/j.tet.2015.04.074

  日期：2015.6

  organometallic reagents has attracted the attention of organic chemists for a long time. However limited methods are reliable for common amides and have found synthetic applications. Here we report a method featuring in situ activation of tertiary amides with triflic anhydride (Tf2O) followed by addition of Grignard reagents. The method displays a good generality in scope for both amides and Grignard reagents

  通过添加有机金属试剂将酰胺直接转化为酮已引起有机化学家的长期关注。然而，有限的方法对于常见的酰胺是可靠的并且已经发现了合成应用。在这里我们报告了一种方法，其特征是用三氟甲磺酸酐（Tf 2 O）原位活化叔酰胺，然后加入格氏试剂。该方法在酰胺和格利雅试剂上都显示出良好的通用性，可以看作是使用酰胺作为稳定和选择性的酰化剂对格利雅试剂进行的酰化反应。而且，该脱氨基烷基化反应提供了一种温和的方法，用于酰胺的N-脱酰作用以得到游离的胺。